You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Colorcon
AstraZeneca
Merck
Mallinckrodt

Last Updated: March 1, 2021

DrugPatentWatch Database Preview

Baricitinib - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for baricitinib and what is the scope of patent protection?

Baricitinib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baricitinib has fifty-four patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for baricitinib
International Patents:54
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 93
Clinical Trials: 67
Patent Applications: 834
DailyMed Link:baricitinib at DailyMed
Recent Clinical Trials for baricitinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
First affiliated Hospital Xi'an Jiaoting UniversityPhase 3
M Abdur Rahim Medical College and HospitalPhase 3
Manchester Clinical Trials UnitPhase 2

See all baricitinib clinical trials

Pharmacology for baricitinib

US Patents and Regulatory Information for baricitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-002 Oct 8, 2019 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for baricitinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2288610 132017000078559 Italy   Start Trial PRODUCT NAME: BARICITINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(OLUMIANT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1170, 20170215
2288610 315 50012-2017 Slovakia   Start Trial PRODUCT NAME: BARICITINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1170 20170215
2288610 2017C/025 Belgium   Start Trial PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610 1790035-8 Sweden   Start Trial PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.